Century Therapeutics, Inc. Payments to Acquire Debt Securities, Available-for-sale
Century Therapeutics, Inc. (IPSC) reported Payments to Acquire Debt Securities, Available-for-sale of $156.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-12
- Century Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $15.97M, a 65.17% increase year-over-year.
- Century Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $140.69M, a 845.19% increase year-over-year.
- Century Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $15.60M, a 10.37% decline year-over-year.
- Century Therapeutics, Inc. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $11.02M, a 16.48% decline year-over-year.
- Century Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2025 was $51.17M, a 57.19% decline from fiscal 2024.
- Century Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2024 was $119.55M, a 42.81% decline from fiscal 2023.
- Century Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2023 was $209.03M, a 17.70% decline from fiscal 2022.
- Century Therapeutics, Inc. payments to acquire debt securities, available-for-sale for fiscal 2022 was $254.00M, a 23.04% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $15.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $156.66M 10-Q · filed 2026-08-12 | $172.26M derived: sum of 3 quarters · filed 2026-08-12 | $183.28M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $140.69M 10-Q · filed 2026-05-13 | $156.29M derived: sum of 2 quarters · filed 2026-05-13 | $167.31M derived: sum of 3 quarters · filed 2026-05-13 | $176.98M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $15.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $26.62M derived: sum of 2 quarters · filed 2026-03-12 | $36.29M derived: sum of 3 quarters · filed 2026-08-12 | $51.17M 10-K · filed 2026-03-12 |
| 2025-09-30 | $11.02M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $20.69M derived: sum of 2 quarters · filed 2026-08-12 | $35.58M 10-Q · filed 2025-11-13 | $52.98M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $9.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $24.55M 10-Q · filed 2026-08-12 | $41.95M derived: sum of 3 quarters · filed 2026-08-12 | $55.15M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $14.88M 10-Q · filed 2026-05-13 | $32.29M derived: sum of 2 quarters · filed 2026-05-13 | $45.49M derived: sum of 3 quarters · filed 2026-05-13 | $99.35M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $17.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $30.60M derived: sum of 2 quarters · filed 2026-03-12 | $84.46M derived: sum of 3 quarters · filed 2026-03-12 | $119.55M 10-K · filed 2026-03-12 |
| 2024-09-30 | $13.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $67.06M derived: sum of 2 quarters · filed 2025-11-13 | $102.14M 10-Q · filed 2025-11-13 | $111.84M derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $53.86M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $88.95M 10-Q · filed 2025-08-14 | $98.64M derived: sum of 3 quarters · filed 2025-08-14 | $156.14M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $35.09M 10-Q · filed 2025-05-15 | $44.78M derived: sum of 2 quarters · filed 2025-05-15 | $102.28M derived: sum of 3 quarters · filed 2025-05-15 | $201.29M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | $9.69M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-19 | $67.19M derived: sum of 2 quarters · filed 2025-03-19 | $166.21M derived: sum of 3 quarters · filed 2025-03-19 | $209.03M 10-K · filed 2025-03-19 |
| 2023-09-30 | $57.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $156.51M derived: sum of 2 quarters · filed 2024-11-05 | $199.34M 10-Q · filed 2024-11-05 | $249.68M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $99.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $141.84M 10-Q · filed 2024-08-08 | $192.18M derived: sum of 3 quarters · filed 2024-08-08 | $258.56M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $42.83M 10-Q · filed 2024-05-09 | $93.17M derived: sum of 2 quarters · filed 2024-05-09 | $159.55M derived: sum of 3 quarters · filed 2024-05-09 | $193.77M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $50.34M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $116.72M derived: sum of 2 quarters · filed 2024-03-14 | $150.94M derived: sum of 3 quarters · filed 2024-03-14 | $254.00M 10-K · filed 2024-03-14 |
| 2022-09-30 | $66.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $100.60M derived: sum of 2 quarters · filed 2023-11-09 | $203.66M 10-Q · filed 2023-11-09 | $245.55M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $34.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $137.28M 10-Q · filed 2023-08-09 | $179.17M derived: sum of 3 quarters · filed 2023-08-09 | $325.25M derived: sum of 4 quarters · filed 2023-08-09 |
| 2022-03-31 | $103.06M 10-Q · filed 2023-05-11 | $144.95M derived: sum of 2 quarters · filed 2023-05-11 | $291.02M derived: sum of 3 quarters · filed 2023-05-11 | $308.24M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $41.89M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $187.97M derived: sum of 2 quarters · filed 2023-03-16 | $205.18M derived: sum of 3 quarters · filed 2023-03-16 | $330.03M 10-K · filed 2023-03-16 |
| 2021-09-30 | $146.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $163.30M derived: sum of 2 quarters · filed 2022-11-10 | $288.15M 10-Q · filed 2022-11-10 | $325.07M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $17.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $142.07M 10-Q · filed 2022-08-11 | $179.00M derived: sum of 3 quarters · filed 2022-08-11 | $187.51M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $124.85M 10-Q · filed 2022-05-16 | $161.78M derived: sum of 2 quarters · filed 2022-05-16 | $170.29M derived: sum of 3 quarters · filed 2022-05-16 | |
| 2020-12-31 | $36.93M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | $45.45M derived: sum of 2 quarters · filed 2022-03-17 | $49.86M 10-K · filed 2022-03-17 | |
| 2020-09-30 | $8.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $12.93M 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $4.42M 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |